Alunbrig
Chemical Name | brigatinib |
Dosage Form | Tablet (oral; 30 mg, 90 mg, 180 mg) |
Drug Class | Kinase inhibitors |
System | Respiratory |
Company | Takeda Pharmaceutical Company Limited |
Approval Year | 2017 |
Indication
- For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.